WIKIMEDIA, NIAIDA DNA vaccine against Zika virus has shown promising results in an early human trial. The results appeared yesterday (October 4) in the New England Journal of Medicine.
“Zika virus continues to be a threat to people living in the Americas and the Caribbean,” lead author Pablo Tebas, a professor of infectious diseases at the University of Pennsylvania, says in a release. “With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika.”
The vaccine, developed by Inovio Pharmaceuticals and GeneOne Life Science, is composed of a ring of DNA (a plasmid) containing the genetic instructions for producing Zika virus antigens. In the study, 40 study participants received three doses of the vaccine through injections under the skin. Patients were then exposed to a device that sends out ...
.jpg){kind=link}